| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 277 | 2020 |
| Weekly Selinexor, Bortezomib and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Patients with Multiple Myeloma (MM) After 1–3 Prior Therapies … MA Dimopoulos, S Delimpasi, M Simonova, I Spicka, L Pour, I Kriachok, ... | 32 | 2020 |
| Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk S Richard, A Chari, S Delimpasi, M Simonova, I Spicka, L Pour, I Kriachok, ... American Journal of Hematology 96 (9), 1120-1130, 2021 | 26 | 2021 |
| Активні форми кисню та їх роль у метаболізмі клітин МІ Колісник, ГВ Колісник, Є Нідзюлка, ВВ Влізло Біологія тварин 11 (1-2), 58-69, 2009 | 26 | 2009 |
| Каротиноїди: будова, властивості та біологічна дія М Сімонова Біологічні студії 4 (2), 159-170, 2010 | 24 | 2010 |
| Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma HW Auner, M Gavriatopoulou, S Delimpasi, M Simonova, I Spicka, L Pour, ... American Journal of Hematology 96 (6), 708-718, 2021 | 21 | 2021 |
| Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma MV Mateos, M Gavriatopoulou, T Facon, HW Auner, X Leleu, R Hájek, ... Journal of Hematology & Oncology 14, 1-5, 2021 | 18 | 2021 |
| Clinical outcomes in patients (Pts) with dose reduction of selinexor in combination with bortezomib, and dexamethasone (XVd) in previously treated multiple myeloma from the … S Jagannath, T Facon, AZ Badros, M Levy, P Moreau, S Delimpasi, ... Blood 138, 3793, 2021 | 11 | 2021 |
| Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone L Sanchez, X Leleu, JL Beaumont, H Yu, S Hudgens, M Simonova, ... American journal of hematology 96 (10), E383-E386, 2021 | 9 | 2021 |
| Стан вільнорадикального окиснення і антиоксидантної системи захисту у щурів при згодовуванні дріжджів Phaffia rhodozyma МІ Колісник, НІ Борецька, ЛІ Сологуб Біол. тварин 9 (1-2), 203-207, 2007 | 9 | 2007 |
| Once weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma: high-risk … S Richard, A Chari, S Delimpasi, M Simonova, I Spicka, L Pour, ... Blood 136, 35-36, 2020 | 6 | 2020 |
| Вплив біомаси каротиносинтезуючих дріжджів Phaffia rhodozyma на стан антиоксидантної системи печінки при інтоксикації щурів тетрахлоретаном МІ Колісник, НІ Борецька, МВ Камінська Мед. хімія 9 (3), 37-40, 2007 | 6 | 2007 |
| Once weekly selinexor, bortezomib, and dexamethasone versus twice weekly bortezomib and dexamethasone in relapsed or refractory multiple myeloma: age and frailty subgroup … HW Auner, M Gavriatopoulou, S Delimpasi, M Simonova, I Spicka, L Pour, ... Blood 136, 17-18, 2020 | 4 | 2020 |
| Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with … X Leleu, MV Mateos, S Jagannath, S Delimpasi, M Simonova, I Spicka, ... Journal of Clinical Oncology 39 (15_suppl), 8024-8024, 2021 | 3 | 2021 |
| Erythropoietin as an independent prognostic factor in myelodysplastic syndromes O Boyko, M Simonova, N Knysh, O Danysh, Y Vygovska, Z Masliak Experimental Oncology 43 (1), 41-45, 2021 | 3 | 2021 |
| Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study. T Facon, HW Auner, M Gavriatopoulou, S Delimpasi, M Simonova, ... Journal of Clinical Oncology 39 (15_suppl), 8019-8019, 2021 | 2 | 2021 |
| Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed … Blood 136 ((Supplement 1)), 50-52, 2020 | 2 | 2020 |
| Вплив бiомаси каротиносинтезуючих дрiжджiв Phaffia rhodozyma на стан антиоксидантної системи печiнки при iнтоксикацiї щурiв тетрахлорметаном МI Колiсник, НI Борецька, МВ Камiнська Медична хiмiя. 9 (3), 37, 2007 | 2 | 2007 |
| Weekly selinexor, bortezomib, and dexamethasone versus twice weekly bortezomib and dexamethasone in patients with multiple myeloma after one to three prior therapies: Initial … MA Dimopoulos, S Delimpasi, M Simonova ASCO20 Virtual Scientific Program. Abstract 8501, 0 | 2 | |
| Immune cytopenias in patients with chronic lymphocytic leukemia (peculiarities, prognostic markers) O Vygovska, N Knysh, M Simonova, I Dzis, T Horodyska, O Boyko, ... Proceeding of the Shevchenko Scientific Society. Medical Sciences 65 (2), 2021 | 1 | 2021 |
